This is a Single Patient Investigational New Drug (IND) to golimumab subcutaneous (SC) for the treatment of recently diagnosed Stage 3 type-1 diabetes mellitus (T1D) in children and young adults. The main purpose of a single patient IND is to provide treatment to participants with serious/life-threatening diseases or conditions prior to marketing authorization.
Participants will receive subcutaneous (SC) golimumab, where doses will be based on weight and/or body surface area.
Other Name: SIMPONI
Rady Children's Hospital
San Diego, California, 92123
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC